

CITATION REPORT

List of articles citing

Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension

DOI: 10.1161/circresaha.118.313356
Circulation Research, 2019, 124, 846-855.

Source: <https://exaly.com/paper-pdf/74694344/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
72	Advances in the molecular regulation of endothelial BMP9 signalling complexes and implications for cardiovascular disease. <i>Biochemical Society Transactions</i> , 2019 , 47, 779-791	5.1	8
71	Response by Guignabert et al to Letter Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". <i>Circulation Research</i> , 2019 , 124, e82-e83	15.7	2
70	Letter by Morrell et al Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". <i>Circulation Research</i> , 2019 , 124, e81	15.7	2
69	The Janus Faces of Bone Morphogenetic Protein 9 in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2019 , 124, 822-824	15.7	6
68	[New insights in the pathogenesis of pulmonary arterial hypertension]. <i>Revue Des Maladies Respiratoires</i> , 2019 , 36, 433-437	0	2
67	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 575-585	10.2	46
66	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020 , 116, 885-893	9.9	35
65	Endothelial Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2605-2618	9.4	11
64	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. 2020 , 11, 1623-1639		9
63	Stem/Progenitor Cells and Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 167-178	9.4	6
62	The protective effects of MSC-EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 13938-13948	5.6	10
61	Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?. <i>GeroScience</i> , 2020 , 42, 1475-1498.9		5
60	There and Back Again: Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. <i>Genes</i> , 2020 , 11,	4.2	3
59	BMP-9 and LDL crosstalk regulates ALK-1 endocytosis and LDL transcytosis in endothelial cells. <i>Journal of Biological Chemistry</i> , 2020 , 295, 18179-18188	5.4	7
58	Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells. <i>Angiogenesis</i> , 2020 , 23, 699-714	10.6	14
57	Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 129, 110355	7.5	6
56	Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension. 2020 ,		1

55	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 766-782	9.4	27
54	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
53	Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021 , 178, 6-30	8.6	42
52	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021 , 117, 1391-1401	9.9	5
51	BMP9 and BMP10 Act Directly on Vascular Smooth Muscle Cells for Generation and Maintenance of the Contractile State. <i>Circulation</i> , 2021 , 143, 1394-1410	16.7	11
50	Targeting transforming growth factor- β receptors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	16
49	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. <i>Cardiovascular Research</i> , 2021 , 117, 2309-2325	9.9	10
48	Protective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF- β signaling pathway. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00703	3.1	6
47	Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?. <i>Biomedicines</i> , 2021 , 9,	4.8	17
46	Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1303, 209-241	3.6	0
45	The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy. <i>Nature Reviews Cardiology</i> , 2021 , 18, 565-580	14.8	28
44	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. <i>Nature Communications</i> , 2021 , 12, 1720	17.4	9
43	Pyrrrolizidine alkaloid-induced transcriptomic changes in rat lungs in a 28-day subacute feeding study. <i>Archives of Toxicology</i> , 2021 , 95, 2785-2796	5.8	0
42	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2021 ,	9.9	7
41	Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia. <i>European Journal of Internal Medicine</i> , 2021 , 88, 89-95	3.9	1
40	BMP9 and BMP10: two close vascular quiescence partners that stand out. <i>Developmental Dynamics</i> , 2021 ,	2.9	6
39	The biology of bone morphogenetic protein signaling pathway in cerebrovascular system. <i>Chinese Neurosurgical Journal</i> , 2021 , 7, 36	1.6	0
38	Endothelial cells in the pathogenesis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	30

37	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. <i>Nature Communications</i> , 2021 , 12, 6177	17.4	5
36	The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?. <i>Cancers</i> , 2021 , 13,	6.6	1
35	Dysfunction and Restoration of Endothelial Cell Communications in Pulmonary Arterial Hypertension: Therapeutic Implications. 2020 , 147-155		
34	A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension. <i>Clinical and Experimental Hypertension</i> , 2021 , 1-6	2.2	
33	A Wrinkle in Time: Circadian biology in pulmonary vascular health and disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021 ,	5.8	1
32	Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF- β Superfamily Signaling.. <i>Frontiers in Medicine</i> , 2021 , 8, 814222	4.9	1
31	Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival.. <i>Pulmonary Circulation</i> , 2022 , 12, e12007	2.7	
30	[Hepatopulmonary syndrome: Prevalence, pathophysiology and clinical implications].. <i>Revue Des Maladies Respiratoires</i> , 2022 , 39, 84-89	0	0
29	Endoglin and Activin Receptor-like Kinase 1 (Alk1) Modify Adrenomedullin Expression in an Organ-Specific Manner in Mice.. <i>Biology</i> , 2022 , 11,	4.9	0
28	Decoding ceRNA regulatory network in the pulmonary artery of hypoxia-induced pulmonary hypertension (HPH) rat model.. <i>Cell and Bioscience</i> , 2022 , 12, 27	9.8	0
27	CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.. <i>Respiratory Research</i> , 2022 , 23, 87	7.3	0
26	An Emerging Class of New Therapeutics Targeting TGF, Activin and BMP Ligands in Pulmonary Arterial Hypertension.. <i>Developmental Dynamics</i> , 2022 ,	2.9	
25	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. <i>Pharmacology & Therapeutics</i> , 2022 , 108192	13.9	1
24	New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.. <i>Circulation Research</i> , 2022 , 130, 1365-1381	15.7	3
23	Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022 ,	5.7	0
22	Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension.. <i>Hypertension</i> , 2022 , 101161HYPERTENSIONAHA12218261	8.5	2
21	Mechanistic and therapeutic perspectives of baicalin and baicalein on pulmonary hypertension: A comprehensive review. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 151, 113191	7.5	3
20	Maresin 1 intervention Reverses Experimental Pulmonary Arterial Hypertension in mice. <i>British Journal of Pharmacology</i> ,	8.6	1

19	Inhibition of immunoglobulin E attenuates pulmonary hypertension. 2022 , 1, 665-678		0
18	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5-4	3
17	Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6R α 2022 , 12,		0
16	BMPR1A Promotes ID2-ZEB1 Interaction to Suppress Excessive Endothelial to Mesenchymal Transition.		0
15	Atheroprone fluid shear stress-regulated ALK1-Endoglin-SMAD signaling originates from early endosomes. 2022 , 20,		0
14	Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT and is associated with pulmonary hypertension.		1
13	Endothelial mechanosensing: A forgotten target to treat vascular remodeling in hypertension?. 2022 , 206, 115290		0
12	Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca ²⁺ Signaling.		1
11	Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. ard-2022-223237		2
10	Targeting BMPR-II in pulmonary arterial hypertension: A case of Hercules versus the Hydra?.		0
9	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. 2023 , 19, e1011063		0
8	Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. 2023 , 24, 3332		0
7	Inhibition of Soluble Epoxide Hydrolase Does Not Promote or Aggravate Pulmonary Hypertension in Rats. 2023 , 12, 665		0
6	Pulmonary Vascular Remodeling in Pulmonary Hypertension. 2023 , 13, 366		0
5	Dysfonction de la signalisation endothéliale du BMP-9 dans les maladies vasculaires pulmonaires. 2023 , 40, 234-238		0
4	Insights into bone morphogenetic proteins in cardiovascular diseases. 14,		0
3	Pathophysiology and new advances in pulmonary hypertension. 2023 , 2, e000137		0
2	Emerging biologics for the treatment of pulmonary arterial hypertension. 1-22		0

1 GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension. **2023**, 13,

o